Geron Corporation达到了Q1收入预期值, Geron Corporation met Q1 earnings expectations, with analysts rating it a "Moderate Buy" at $5.68 target.

Geron公司是一家发展治疗血癌的生物制药公司,它报告说,Q1收入达到分析师预期的(0.04美元)EPS,收入47.54M美元。 Geron Corporation, a biopharmaceutical firm developing treatments for blood cancers, reported Q1 earnings meeting analyst expectations of ($0.04) EPS with $47.54M in revenue. 分析师调整了评级和价格目标,达成了“机动买”共识,目标价格为5.68美元。 Analysts have adjusted their ratings and price targets, resulting in a "Moderate Buy" consensus and a target price of $5.68. 机构投资者拥有73.71%的股票,价值10.5亿美元的市场上限。 Institutional investors own 73.71% of the stock, valued at a market cap of $1.05 billion. Geron的主要药物Imetelstat, 正在第3阶段试验中。 Geron's lead drug, imetelstat, is in Phase 3 trials.